396 related articles for article (PubMed ID: 25147328)
21. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
[TBL] [Abstract][Full Text] [Related]
22. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
Billings FT; Hendricks PA; Schildcrout JS; Shi Y; Petracek MR; Byrne JG; Brown NJ
JAMA; 2016 Mar; 315(9):877-88. PubMed ID: 26906014
[TBL] [Abstract][Full Text] [Related]
23. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
Amarenco P; Bogousslavsky J; Callahan AS; Goldstein L; Hennerici M; Sillsen H; Welch MA; Zivin J;
Cerebrovasc Dis; 2003; 16(4):389-95. PubMed ID: 14584489
[TBL] [Abstract][Full Text] [Related]
24. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Goldstein LB; Amarenco P; Zivin J; Messig M; Altafullah I; Callahan A; Hennerici M; MacLeod MJ; Sillesen H; Zweifler R; Michael K; Welch A;
Stroke; 2009 Nov; 40(11):3526-31. PubMed ID: 19745172
[TBL] [Abstract][Full Text] [Related]
25. The atorvastatin during ischemic stroke study: a pilot randomized controlled trial.
Muscari A; Puddu GM; Santoro N; Serafini C; Cenni A; Rossi V; Zoli M
Clin Neuropharmacol; 2011; 34(4):141-7. PubMed ID: 21677574
[TBL] [Abstract][Full Text] [Related]
26. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
Rutter MK; Prais HR; Charlton-Menys V; Gittins M; Roberts C; Davies RR; Moorhouse A; Jinadev P; France M; Wiles PG; Gibson JM; Dean J; Kalra PA; Cruickshank JK; Durrington PN
Diabet Med; 2011 Jan; 28(1):100-8. PubMed ID: 21166851
[TBL] [Abstract][Full Text] [Related]
27. Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
Shepherd J; Breazna A; Deedwania PC; LaRosa JC; Wenger NK; Messig M; Wilson DJ;
Am J Cardiol; 2016 Apr; 117(8):1199-205. PubMed ID: 26940556
[TBL] [Abstract][Full Text] [Related]
28. Expanding roles for atorvastatin.
Singh V; Deedwania P
Drugs Today (Barc); 2008 Jun; 44(6):455-71. PubMed ID: 18596999
[TBL] [Abstract][Full Text] [Related]
29. Stroke--an equal opportunity for the initiation of statin therapy.
Kent DM
N Engl J Med; 2006 Aug; 355(6):613-5. PubMed ID: 16899782
[No Abstract] [Full Text] [Related]
30. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Goldstein LB; Amarenco P; Lamonte M; Gilbert S; Messig M; Callahan A; Hennerici M; Sillesen H; Welch KM;
Stroke; 2008 Sep; 39(9):2444-8. PubMed ID: 18617654
[TBL] [Abstract][Full Text] [Related]
31. Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial.
Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Cardinal JW; Coombes JS
Nephrol Dial Transplant; 2012 Jan; 27(1):182-9. PubMed ID: 21543653
[TBL] [Abstract][Full Text] [Related]
32. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
; Karam JG; Loney-Hutchinson L; McFarlane SI
J Cardiometab Syndr; 2008; 3(1):68-9. PubMed ID: 18326981
[No Abstract] [Full Text] [Related]
33. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
34. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
Shepherd J; Kastelein JP; Bittner VA; Carmena R; Deedwania PC; Breazna A; Dobson S; Wilson DJ; Zuckerman AL; Wenger NK;
Mayo Clin Proc; 2008 Aug; 83(8):870-9. PubMed ID: 18674471
[TBL] [Abstract][Full Text] [Related]
35. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Harris KP; Wheeler DC; Chong CC;
Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
[TBL] [Abstract][Full Text] [Related]
36. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
[TBL] [Abstract][Full Text] [Related]
37. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
[TBL] [Abstract][Full Text] [Related]
38. Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
Deedwania PC; Stone PH; Fayyad RS; Laskey RE; Wilson DJ
Drugs Aging; 2015 Dec; 32(12):1055-65. PubMed ID: 26625880
[TBL] [Abstract][Full Text] [Related]
39. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
Athyros VG; Karagiannis A; Ganotakis ES; Paletas K; Nicolaou V; Bacharoudis G; Tziomalos K; Alexandrides T; Liberopoulos EN; Mikhailidis DP;
Curr Med Res Opin; 2011 Aug; 27(8):1659-68. PubMed ID: 21714711
[TBL] [Abstract][Full Text] [Related]
40. Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials.
Idzerda NMA; Pena MJ; Parving HH; de Zeeuw D; Heerspink HJL
Nephrol Dial Transplant; 2019 Oct; 34(10):1699-1706. PubMed ID: 30184238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
